Contamination and Structural Analogs in the Illicit Phencyclidine Market: Pharmacology, Toxicology, and Public Health Implications of PCE, TCP, 3-MeO-PCP, and Fentanyl Adulteration

Abstract

The illegal PCP (phencyclidine) has recently undergone a significant transformation. One characterized by the proliferation of structurally similar arylcyclohexylamine analogs. As well as the general increasing infiltration of synthetic opioids. This review synthesizes current relevant pharmacological, psychopharmacological, toxicological, forensic, and epidemiological evidence in the literature regarding PCP analogs (i.e., PCE, TCP, and 3-MeO-PCP). That and emerging data concerning fentanyl adulteration in dissociative drug supplies. In order to better understand this data, we performed a structured literature search that was conducted using major biomedical databases and grey literature sources. This also incorporated pharmacodynamic studies, clinical case reports, forensic analyses, and public health surveillance data. The findings down below indicate that even the slightest structural modifications to the PCP scaffold produce substantial variability in receptor binding profiles. Particularly at NMDA, dopamine transporter, and sigma receptor sites. Then, resulting in altered potency, duration of action, and neuropsychiatric toxicity. Novel analogs such as 3-MeO-PCP demonstrate a markedly higher dopaminergic activity and prolonged behavioral effects. Whereas, TCP exhibits high NMDA and sigma receptor affinity associated with more severe psychotomimetic outcomes. At the same time, the expansion of fentanyl into non-opioid drug markets starts to introduce a critical and often underrecognized overdose risk. Mechanistically, however, the combination of NMDA receptor antagonism and mu-opioid receptor agonism may likely produce additive or synergistic toxicity. Consequently, dissociative-induced cognitive impairment delays recognition of opioid-induced respiratory depression. Ultimately, the convergence of structural analogue penetration and opioid adulteration represents a substantial shift in the general risk landscape of dissociative drug usage. Addressing this evolving threat will require something. It requires significantly enhanced toxicological surveillance, more adaptive regulatory frameworks, and expanded harm reduction techniques. Such shall include drug checking services and naloxone distribution. In order to mitigate the ever growing burden of unpredictable and high-risk polysubstance exposure.